>
Switch to:

Biohaven Pharmaceutical Holding Co Asset Turnover

: 0.10 (As of Jun. 2021)
View and export this data going back to 2017. Start your Free Trial

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Biohaven Pharmaceutical Holding Co's Revenue for the three months ended in Jun. 2021 was $92.9 Mil. Biohaven Pharmaceutical Holding Co's Total Assets for the quarter that ended in Jun. 2021 was $924.5 Mil. Therefore, Biohaven Pharmaceutical Holding Co's Asset Turnover for the quarter that ended in Jun. 2021 was 0.10.

Asset Turnover is linked to ROE % through Du Pont Formula. Biohaven Pharmaceutical Holding Co's annualized ROE % for the quarter that ended in Jun. 2021 was 230.86%. It is also linked to ROA % through Du Pont Formula. Biohaven Pharmaceutical Holding Co's annualized ROA % for the quarter that ended in Jun. 2021 was -91.13%.


Biohaven Pharmaceutical Holding Co Asset Turnover Historical Data

The historical data trend for Biohaven Pharmaceutical Holding Co's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Pharmaceutical Holding Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Asset Turnover
Premium Member Only - - - - 0.12

Biohaven Pharmaceutical Holding Co Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Asset Turnover Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.03 0.05 0.05 0.10

Biohaven Pharmaceutical Holding Co Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Biohaven Pharmaceutical Holding Co's Asset Turnover for the fiscal year that ended in Dec. 2020 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2020 )/( (Total Assets (A: Dec. 2019 )+Total Assets (A: Dec. 2020 ))/ count )
=63.627/( (344.264+686.975)/ 2 )
=63.627/515.6195
=0.12

Biohaven Pharmaceutical Holding Co's Asset Turnover for the quarter that ended in Jun. 2021 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jun. 2021 )/( (Total Assets (Q: Mar. 2021 )+Total Assets (Q: Jun. 2021 ))/ count )
=92.933/( (1003.159+845.893)/ 2 )
=92.933/924.526
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Biohaven Pharmaceutical Holding Co  (NYSE:BHVN) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Biohaven Pharmaceutical Holding Co's annulized ROE % for the quarter that ended in Jun. 2021 is

ROE %**(Q: Jun. 2021 )
=Net Income/Total Stockholders Equity
=-842.476/-364.9265
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-842.476 / 371.732)*(371.732 / 924.526)*(924.526/ -364.9265)
=Net Margin %*Asset Turnover*Equity Multiplier
=-226.64 %*0.4021*-2.5335
=ROA %*Equity Multiplier
=-91.13 %*-2.5335
=230.86 %

Note: The Net Income data used here is four times the quarterly (Jun. 2021) net income data. The Revenue data used here is four times the quarterly (Jun. 2021) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Biohaven Pharmaceutical Holding Co's annulized ROA % for the quarter that ended in Jun. 2021 is

ROA %(Q: Jun. 2021 )
=Net Income/Total Assets
=-842.476/924.526
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-842.476 / 371.732)*(371.732 / 924.526)
=Net Margin %*Asset Turnover
=-226.64 %*0.4021
=-91.13 %

Note: The Net Income data used here is four times the quarterly (Jun. 2021) net income data. The Revenue data used here is four times the quarterly (Jun. 2021) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Biohaven Pharmaceutical Holding Co Asset Turnover Related Terms

Thank you for viewing the detailed overview of Biohaven Pharmaceutical Holding Co's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Biohaven Pharmaceutical Holding Co Business Description

Biohaven Pharmaceutical Holding Co logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
C/o Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, CT, USA, 06510
Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV-3100, BHV5000, BHV5500, among others.
Executives
Bailey Gregory director 4 A CHESHAM STREET LONDON X0 SW1X8DT
Gentile Kimberly officer: SVP, Clinical Operations C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Childs John W director 111 HUNTINGTON AVENUE SUITE 2900 BOSTON MA 02199
Berman Robert officer: Special Projects & Med Ovrsght C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Doogan Declan director C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Stock Elyse officer: Chief Medical Officer 215 CHURCH STREET NEW HAVEN CT 06510
Engelhart James officer: Chief Financial Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Tilton John officer: Chief Commercial Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Hugin Robert J director C/O THE MEDICINES CO 8 CAMPUS DR PARSIPPANY NJ 07054
Heffernan Michael Thomas director C/O CORNERSTONE THERAPEUTICS INC. 1255 CRESCENT GREEN DRIVE, SUITE 250 CARY NC 27518
Gregory Julia P director 8800 TECHNOLOGY FOREST PLACE THE WOODLANDS TX 77381
Aguiar Eric director 888 7TH AVENUE 12TH FLOOR NEW YORK NY 10106
Coric Vlad director, officer: Chief Executive Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Jones William A Jr officer: CCO-Migraine & Common Disease NITROMED, INC. 125 SPRING STREET LEXINGTON MA 02421
Conway Charles officer: Chief Scientific Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510

Biohaven Pharmaceutical Holding Co Headlines

From GuruFocus

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)